UY39522A - Anticuerpos de cadena pesada que se unen al receptor alfa de folato - Google Patents

Anticuerpos de cadena pesada que se unen al receptor alfa de folato

Info

Publication number
UY39522A
UY39522A UY0001039522A UY39522A UY39522A UY 39522 A UY39522 A UY 39522A UY 0001039522 A UY0001039522 A UY 0001039522A UY 39522 A UY39522 A UY 39522A UY 39522 A UY39522 A UY 39522A
Authority
UY
Uruguay
Prior art keywords
heavy
chain antibodies
bind
alpha receptor
folate
Prior art date
Application number
UY0001039522A
Other languages
English (en)
Inventor
Nathan Trinklein
Katherine Harris
Brian Avanzino
Hannes Kehm
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of UY39522A publication Critical patent/UY39522A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen anticuerpos de cadena pesada del receptor alfa anti-folato (FOLR1) (por ejemplo, UniAbsTM), junto con métodos para elaborar tales anticuerpos, composiciones, incluidas las composiciones farmacéuticas, que comprenden dichos anticuerpos, y su uso para tratar trastornos que se caracterizan por la expresión del receptor alfa de folato (FOLR1).
UY0001039522A 2020-11-18 2021-11-18 Anticuerpos de cadena pesada que se unen al receptor alfa de folato UY39522A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063115436P 2020-11-18 2020-11-18

Publications (1)

Publication Number Publication Date
UY39522A true UY39522A (es) 2022-06-30

Family

ID=79024440

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039522A UY39522A (es) 2020-11-18 2021-11-18 Anticuerpos de cadena pesada que se unen al receptor alfa de folato

Country Status (17)

Country Link
US (1) US20240002498A1 (es)
EP (1) EP4247498A1 (es)
JP (1) JP2023549851A (es)
KR (1) KR20230110303A (es)
CN (1) CN116615253A (es)
AR (1) AR124084A1 (es)
AU (1) AU2021383743A1 (es)
CA (1) CA3199785A1 (es)
CL (1) CL2023001432A1 (es)
CO (1) CO2023006790A2 (es)
CR (1) CR20230259A (es)
IL (1) IL302670A (es)
MX (1) MX2023005693A (es)
PE (1) PE20231203A1 (es)
TW (1) TW202233684A (es)
UY (1) UY39522A (es)
WO (1) WO2022109010A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
MX2021015337A (es) 2019-06-14 2022-01-18 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
PL2406284T3 (pl) 2009-03-10 2017-09-29 Biogen Ma Inc. Przeciwciała anty-bcma
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
EP3789402B1 (en) * 2014-11-20 2022-07-13 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
JP7146395B2 (ja) * 2014-11-20 2022-10-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ＦｏｌＲ１及びＣＤ３を標的とする二重特異性抗体
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
US20190225671A1 (en) 2016-08-24 2019-07-25 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
PT4050034T (pt) 2016-09-14 2024-05-27 Teneoone Inc Anticorpos de ligação a cd3
SG11202007494TA (en) * 2018-03-13 2020-09-29 Phanes Therapeutics Inc Anti-folate receptor 1 antibodies and uses thereof

Also Published As

Publication number Publication date
AU2021383743A9 (en) 2024-09-26
PE20231203A1 (es) 2023-08-17
EP4247498A1 (en) 2023-09-27
JP2023549851A (ja) 2023-11-29
MX2023005693A (es) 2023-05-29
IL302670A (en) 2023-07-01
TW202233684A (zh) 2022-09-01
CL2023001432A1 (es) 2024-01-05
WO2022109010A1 (en) 2022-05-27
AR124084A1 (es) 2023-02-08
KR20230110303A (ko) 2023-07-21
AU2021383743A1 (en) 2023-06-08
US20240002498A1 (en) 2024-01-04
CR20230259A (es) 2023-07-13
CN116615253A (zh) 2023-08-18
CO2023006790A2 (es) 2023-06-09
CA3199785A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
CL2021002586A1 (es) Anticuerpos de cadena pesada que se unen al psma
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2023006790A2 (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
AR119746A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CL2016002585A1 (es) Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373)
CL2018003438A1 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos.
BR112016004073A8 (pt) Anticorpos criados por engenharia, conjugados de anticorpo fármaco, seu método de preparação e seu uso, composição farmacêutica e seu uso, kits, e métodos para administrar uma pirrolobenzodiazepina (pbd) a uma célula de câncer que expressa dll3 e para determinar a citotoxicidade de um conjugado de anticorpo fármaco anti-dll3
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
DOP2022000229A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CL2022002247A1 (es) Anticuerpos de cadena pesada que se unen a cd22 (divisional de la solicitud 202001703)
UY39191A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
BR112016020871A2 (pt) anticorpos anti-mcam e métodos associados de uso
UY39715A (es) Anticuerpos anti-il-2r agonistas y métodos de uso
CL2023003073A1 (es) Anticuerpos anti-cd20 y estructuras car-t
MX2020004265A (es) Conjugados de anticuerpos y farmacos de factor anti-tisular y su uso en el tratamiento del cancer.
CO2023000808A2 (es) Unión de anticuerpos multiespecíficos a bcma
CL2023001220A1 (es) Inhibidores de interleucina-17
CO2023013500A2 (es) Anticuerpos anti-cd19 y estructuras car-t
CL2022001677A1 (es) Anticuerpos anti-ccl2 biespecíficos
MX2019015120A (es) Composicion y metodo para el tratamiento de la depresion y psicosis en humanos.
BR112022013553A2 (pt) Composição farmacêutica, anticorpo, e, método para tratar uma doença